Smith & Nephew Snats ( (SNN) ) just unveiled an announcement.
On March 10, 2025, Smith & Nephew plc released its annual report for the fiscal year 2024, highlighting significant financial achievements and strategic progress. The report indicates a 54.6% increase in operating profit and a 57.3% rise in trading cash flow, reflecting the company’s successful implementation of its 12-Point Plan aimed at enhancing productivity and growth. The company has seen positive outcomes in its orthopaedics, sports medicine, and advanced wound management sectors, with expectations for continued progress in 2025. This strategic advancement positions Smith & Nephew strongly within its industry, with a focus on innovation and customer-centric solutions.
More about Smith & Nephew Snats
Smith & Nephew is a leading medical technology company with a focus on orthopaedics, sports medicine, ear, nose and throat (ENT), and advanced wound management. The company operates in global markets valued at approximately $50 billion annually, driven by long-term growth factors and technological advancements. Smith & Nephew is committed to innovation and improving productivity, aiming to transform into a sustainably higher-growth company.
YTD Price Performance: 22.38%
Average Trading Volume: 805,331
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $12.98B
Find detailed analytics on SNN stock on TipRanks’ Stock Analysis page.